Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Offidani

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupAntonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, et al.
Blood Cancer Journal|July 19, 2022
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian studyLivio Pagano, Marianna Criscuolo, Alessandro Broccoli, et al.
American Journal of Hematology|November 26, 2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyFortunato Morabito, Sara Bringhen, Alessandra Larocca, et al.
The Lancet. Oncology|September 17, 2023
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 studyNiels W C J van de Donk, Monique C Minnema, Bronno van der Holt, et al.
European Journal of Haematology|January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' RecommendationsAlessandro Corso, Monia Marchetti, Monica Galli, et al.
Haematologica|March 26, 2026
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experienceCarmine Liberatore, Virginia Valeria Ferretti, Paola Tacchetti, et al.
Blood Advances|August 19, 2025
Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysisAndrew Spencer, Maria Gavriatopoulou, Daniel Coriu, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, et al.
European Journal of Haematology|October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patientsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupAntonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, et al.
Blood Cancer Journal|July 19, 2022
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian studyLivio Pagano, Marianna Criscuolo, Alessandro Broccoli, et al.
American Journal of Hematology|November 26, 2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyFortunato Morabito, Sara Bringhen, Alessandra Larocca, et al.
The Lancet. Oncology|September 17, 2023
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 studyNiels W C J van de Donk, Monique C Minnema, Bronno van der Holt, et al.
European Journal of Haematology|January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' RecommendationsAlessandro Corso, Monia Marchetti, Monica Galli, et al.
Haematologica|March 26, 2026
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experienceCarmine Liberatore, Virginia Valeria Ferretti, Paola Tacchetti, et al.
Blood Advances|August 19, 2025
Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysisAndrew Spencer, Maria Gavriatopoulou, Daniel Coriu, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, et al.
European Journal of Haematology|October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patientsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Pageof 15